OrthoPediatrics Corp. (NASDAQ:KIDS) Given Average Recommendation of “Moderate Buy” by Analysts

OrthoPediatrics Corp. (NASDAQ:KIDS) has been assigned a consensus recommendation of “Moderate Buy” from the eleven brokerages that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and nine have given a buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $26.4444.

A number of brokerages have weighed in on KIDS. Truist Financial set a $22.00 target price on shares of OrthoPediatrics in a research note on Wednesday, August 5th. BTIG Research boosted their price target on OrthoPediatrics from $24.00 to $29.00 and gave the stock a “buy” rating in a research report on Thursday, August 20th. Piper Sandler restated an “overweight” rating and issued a $25.00 price target (up from $22.00) on shares of OrthoPediatrics in a research note on Wednesday, August 5th. Weiss Ratings raised OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, August 5th. Finally, TD Cowen reaffirmed a “buy” rating on shares of OrthoPediatrics in a research report on Monday, June 15th.

OrthoPediatrics Stock Down 2.3%

Shares of OrthoPediatrics stock opened at $24.50 on Wednesday. The company has a debt-to-equity ratio of 0.28, a current ratio of 4.78 and a quick ratio of 2.17. The company has a 50-day moving average of $21.11 and a 200 day moving average of $18.53. The firm has a market cap of $639.70 million, a price-to-earnings ratio of -14.58 and a beta of 0.98. OrthoPediatrics has a 1 year low of $14.42 and a 1 year high of $26.74.

OrthoPediatrics (NASDAQ:KIDS) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.04. OrthoPediatrics had a negative net margin of 15.72% and a negative return on equity of 8.10%. The company had revenue of $70.51 million during the quarter, compared to analysts’ expectations of $68.21 million. As a group, sell-side analysts anticipate that OrthoPediatrics will post -1.14 earnings per share for the current fiscal year.

Hedge Funds Weigh In On OrthoPediatrics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Millennium Management LLC raised its position in shares of OrthoPediatrics by 48.0% in the 4th quarter. Millennium Management LLC now owns 1,396,495 shares of the company’s stock worth $24,802,000 after purchasing an additional 452,840 shares during the last quarter. BlackRock Inc. bought a new position in OrthoPediatrics in the 2nd quarter worth about $24,347,000. Vanguard Group Inc. grew its position in OrthoPediatrics by 1.1% during the 3rd quarter. Vanguard Group Inc. now owns 961,330 shares of the company’s stock valued at $17,813,000 after purchasing an additional 10,927 shares during the last quarter. Granahan Investment Management LLC grew its position in OrthoPediatrics by 35.1% during the 1st quarter. Granahan Investment Management LLC now owns 896,741 shares of the company’s stock valued at $14,231,000 after purchasing an additional 232,760 shares during the last quarter. Finally, Wasatch Advisors LP grew its position in OrthoPediatrics by 56.6% during the 2nd quarter. Wasatch Advisors LP now owns 515,677 shares of the company’s stock valued at $9,865,000 after purchasing an additional 186,357 shares during the last quarter. 69.05% of the stock is currently owned by institutional investors.

About OrthoPediatrics

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.